Novel ALL treatment strategies: CAR T-cells
Description: CAR T-cells are a universally exciting area in hematological oncology. Speaking from the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA, Elias Jabbour, MD, of the University of Texas MD Anderson Cancer Center, Houston, TX, discusses the landscape of CAR T-cell therapy for acute lymphoblastic leukemia (ALL). He covers the approval of the CAR T-cell product tisagenlecleucel for pediatric and adolescent ALL based on data from the Phase II ELIANA trial (NCT02435849). Dr Jabbour also discusses the landscape of this field moving forwards, including the potentially game-changing use of off-the-shelf allogeneic CAR T-cell therapy.
Shared By : VJHemOnc
Posted on : 02/22/18
Added : 10 months ago